Masashi Saito

Summary

Publications

  1. ncbi request reprint A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA)
    Masashi Saito
    Seta Clinic Group, Chiyoda ku, Tokyo, Japan
    Anticancer Res 33:2957-63. 2013
  2. doi request reprint Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy
    Atsutaka Noguchi
    Seta Clinic Group, 3 6 5 Iidabashi, Chiyoda ku, Tokyo 102 0072, Japan Medinet Co, Ltd, Shin Yokohama Square Bldg 14F, 2 3 12 Shin Yokohama, Kohoku Ku, Yokohama 222 0033, Japan
    Int Immunopharmacol 18:90-7. 2014
  3. doi request reprint Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors
    Atsutaka Noguchi
    Seta Clinic Group, Seta Clinic Tokyo, 3 6 5 Iidabashi, Chiyoda ku, Tokyo, Japan
    Cytotherapy 13:92-7. 2011

Collaborators

Detail Information

Publications3

  1. ncbi request reprint A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA)
    Masashi Saito
    Seta Clinic Group, Chiyoda ku, Tokyo, Japan
    Anticancer Res 33:2957-63. 2013
    ..Combination of ALA/DCA, hyperthermotherapy, and cellular immunotherapy may be a low-invasive palliative therapy superior in maintaining quality of life of tumor-bearing terminally ill individuals...
  2. doi request reprint Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy
    Atsutaka Noguchi
    Seta Clinic Group, 3 6 5 Iidabashi, Chiyoda ku, Tokyo 102 0072, Japan Medinet Co, Ltd, Shin Yokohama Square Bldg 14F, 2 3 12 Shin Yokohama, Kohoku Ku, Yokohama 222 0033, Japan
    Int Immunopharmacol 18:90-7. 2014
    ..ATI increased the number of T cell subsets, but not B and NK cells. The number and percentage of regulatory T cells decreased significantly. These results suggest that ATI can restore impaired and imbalanced T cell immune status. ..
  3. doi request reprint Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors
    Atsutaka Noguchi
    Seta Clinic Group, Seta Clinic Tokyo, 3 6 5 Iidabashi, Chiyoda ku, Tokyo, Japan
    Cytotherapy 13:92-7. 2011
    ..Zoledronate-activated Vγ9γδ T cell-based immunotherapy that restores the number of Vγ9γδ T cells in cancer patients may provide another mode of adoptive immunotherapy...